Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary hyperaldosteronism.

Sunil Nadar1, Gregory Y H Lip, D Gareth Beevers

  • 1University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.

Annals of Clinical Biochemistry
|September 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An apparent paradox in visit-to-visit blood pressure variability and adverse outcomes in malignant hypertension patients: The West Birmingham malignant hypertension registry.

Current problems in cardiology·2025
Same author

Long-term risk of adverse events in patients discharged alive after hospitalization for hypertensive crisis.

Journal of hypertension·2025
Same author

Characteristics and clinical outcomes in malignant phase hypertension patients using cluster analysis: A report from the West Birmingham Malignant Hypertension Registry.

Current problems in cardiology·2025
Same author

Prediction of major outcomes in patients with malignant hypertension using machine learning: A report from the West Birmingham malignant hypertension registry.

European journal of clinical investigation·2025
Same author

For Debate: The 2023 European Society of Hypertension guidelines - cause for concern.

Journal of hypertension·2024
Same author

β-Blocker Use in Pregnancy and the Risk for Congenital Malformations.

Annals of internal medicine·2019

Primary hyperaldosteronism, a key cause of hypertension, affects up to 10% of patients. Early screening and diagnosis are crucial for effective treatment of this often-overlooked condition.

Area of Science:

  • Endocrinology
  • Nephrology
  • Cardiovascular Medicine

Background:

  • Primary hyperaldosteronism is a significant, yet often underdiagnosed, contributor to hypertension.
  • Its prevalence is estimated to affect up to 10% of hypertensive individuals.
  • Causes include aldosterone-secreting tumors, adrenal hyperplasia, carcinoma, or genetic factors.

Purpose of the Study:

  • To review optimal screening methods for primary hyperaldosteronism.
  • To highlight patient groups who benefit most from screening.
  • To discuss diagnostic and etiological investigations and treatment strategies.

Main Methods:

  • Review of current literature on primary hyperaldosteronism screening and diagnosis.
  • Discussion of various diagnostic tests, including plasma aldosterone-to-renin ratio.

Related Experiment Videos

  • Consideration of imaging and adrenal vein sampling for etiological determination.

    • Main Results:

    • Serum potassium is an unreliable screening marker, potentially missing a third of cases.
    • Plasma aldosterone concentration to plasma renin activity ratio is the preferred screening test.
    • Young patients, those with resistant hypertension, and hypokalemia benefit most from screening.

    Conclusions:

    • Primary hyperaldosteronism is a treatable cause of hypertension requiring systematic identification.
    • Accurate diagnosis through appropriate screening and etiological workup is essential.
    • Treatment involves medical management (spironolactone) or surgical intervention (adrenalectomy).